JP2022526979A5 - - Google Patents
Info
- Publication number
- JP2022526979A5 JP2022526979A5 JP2021559100A JP2021559100A JP2022526979A5 JP 2022526979 A5 JP2022526979 A5 JP 2022526979A5 JP 2021559100 A JP2021559100 A JP 2021559100A JP 2021559100 A JP2021559100 A JP 2021559100A JP 2022526979 A5 JP2022526979 A5 JP 2022526979A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- bifunctional compound
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831267P | 2019-04-09 | 2019-04-09 | |
| US62/831,267 | 2019-04-09 | ||
| PCT/US2020/027236 WO2020210337A1 (en) | 2019-04-09 | 2020-04-08 | Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526979A JP2022526979A (ja) | 2022-05-27 |
| JP2022526979A5 true JP2022526979A5 (cg-RX-API-DMAC7.html) | 2023-04-14 |
| JP7667742B2 JP7667742B2 (ja) | 2025-04-23 |
Family
ID=72750645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559100A Active JP7667742B2 (ja) | 2019-04-09 | 2020-04-08 | Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12642857B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3952871A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7667742B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113645972A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020270908B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134491A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020210337A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478534B (zh) * | 2020-10-24 | 2025-08-05 | 杭州中美华东制药有限公司 | 具有抗肿瘤活性的嵌合分子及其制备方法和应用 |
| WO2024146599A1 (zh) * | 2023-01-06 | 2024-07-11 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途 |
| CN120157686A (zh) * | 2023-12-14 | 2025-06-17 | 南京正大天晴制药有限公司 | 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| IL325256A (en) | 2014-06-13 | 2026-02-01 | Bach Biosciences Llc | FAP-activated medical materials and related uses |
| WO2017185031A1 (en) | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| CN109562107A (zh) * | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| JP2021515013A (ja) * | 2018-03-06 | 2021-06-17 | アイカーン スクール オブ メディスン アット マウント シナイ | セリンスレオニンキナーゼ(akt)分解/破壊化合物および使用方法 |
-
2020
- 2020-04-08 JP JP2021559100A patent/JP7667742B2/ja active Active
- 2020-04-08 EP EP20788177.2A patent/EP3952871A4/en active Pending
- 2020-04-08 US US17/601,640 patent/US12642857B2/en active Active
- 2020-04-08 CN CN202080027366.1A patent/CN113645972A/zh active Pending
- 2020-04-08 WO PCT/US2020/027236 patent/WO2020210337A1/en not_active Ceased
- 2020-04-08 AU AU2020270908A patent/AU2020270908B2/en active Active
- 2020-04-08 CA CA3134491A patent/CA3134491A1/en active Pending